We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics

By LabMedica International staff writers
Posted on 26 Jan 2024

Seegene, Inc. More...

(Seoul, Korea) and Microsoft (Redmond, WA, USA) have entered into a strategic collaboration that opens up a new chapter in the field of molecular diagnostics to realize 'a world free from all diseases and future pandemics'.

Seegene has selected Microsoft as a technology partner for its SG OneSystem business to realize 'a world free from all diseases.' By collaborating with Microsoft to drive the growth of its SG OneSystem business, Seegene has adopted an unprecedented strategy of sharing its unique syndromic quantitative PCR technologies with the world’s leading companies to encourage cross-industry innovation in molecular diagnostics. The expansion of participating companies, with whom Seegene aims to form a global consortium, will empower countries across the world with optimal solutions, enabling them to effectively address future pandemics and collectively move closer to 'a world free from all diseases.'

To achieve this goal, Seegene will work with Microsoft's global healthcare team to help further SG OneSystem's growth by advocating the collective vision, bridging potential partners, and jointly participating in SG OneSystem's annual symposium. Other key events connecting current and prospective SG OneSystem partners, such as a declaration ceremony for scientific communities and other partners participating in the SG OneSystem business will be held within the first half of this year to commemorate the shared vision. Seegene's Digitalized Development System (SGDDS) will integrate Microsoft Azure services, including Azure OpenAI Service, which will be used by Seegene to handle the landscape of data interaction and analysis for researchers dealing with extensive data generated by the SGDDS. The implementation of the highly secure and compliant Azure Trusted Research Environment (TRE) will push the boundaries of PCR research, helping ensure both privacy and regulatory adherence.

Seegene will implement Microsoft Fabric, a single AI-powered analytics platform that will unify Seegene's data and reshape how everyone accesses, manages, and acts on that data with capabilities that span data integration, data engineering, data science, data monitoring, real-time analytics, and business intelligence. The integration of AI-driven assistance through Copilot for Microsoft 365 is expected to accelerate productivity, foster innovation and enhance creativity. Furthermore, Seegene will collaborate with Microsoft on collective healthcare innovation research, including next-generation management and analytics for PCR data, and explore future ventures within the healthcare sector. Seegene aims to improve the healthcare ecosystem with Microsoft by delivering accurate early disease diagnoses that provide the foundation for effective treatment and prevention.

"The strategic collaboration with Microsoft will allow us to have a more structured SG OneSystemTM business model," said Dr. Jong-Yoon Chun, CEO and founder of Seegene. "Through our joint efforts, we expect synergetic effects to pave the way for a world free from all diseases."

"We support Seegene's vision of realizing 'a world free from all diseases,'" added Elena Bonfiglioli, General Manager, Global Health and Life Sciences at Microsoft. "In addition to working with Seegene on its digital transformation, we will collaborate to discover global partners and to further enhance the healthcare ecosystem."

Related Links:
Seegene, Inc.
Microsoft


New
Gold Member
Latex Test
SLE-Latex Test
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Gold Member
Giardia Rapid Test
GIARDIA Cassette
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.